Benitec reports durable swallowing improvements at 180 days for first BB-301 subject in Phase 1b/2a

Benitec Biopharma Inc.

Post-dose Total Pharyngeal Residue meaningfully reduced at 180 days vs pre-dose average for Subject 1.
For 3 of 4 food types, TPR at 180 days lower than any point in 9-month natural history study; fourth similar to lowest.
SSQ Total Score at 180 days lower than any point in 9-month pre-dose period, indicating improved swallowing.
No SAEs observed; transient Grade 2 GERD previously reported.
Second subject dosed Feb 2024; third expected Q3 2024; additional interim data in Q1 2025.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.